Breaking News, Collaborations & Alliances

Roche, Avista Ink Potential $1B Gene Therapy Deal

To develop next-generation AAV vectors for eye diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Avista Therapeutics, a gene therapy developer for rare ophthalmic conditions, has formed a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. Avista recently launched as a spinout from the University of Pittsburgh Medical Center (UPMC). The partnership with Roche aims to apply Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche. Under the terms o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters